vision-restoration
(3)
Ray Therapeutics and the Cells That Refused to Leave
After his daughter's diagnosis, Paul Bresge built one retinal therapy company. Its limits helped point him toward another: a Berkeley biotech trying to turn the eye's surviving cells into new light sensors.
Adaptilens
Adaptilens is a pre-clinical biotechnology company in Newton, Massachusetts developing the first biomimetic accommodating intraocular lens (A-IOL) - a soft, flexible artificial lens that responds to the eye's natural focusing signal from the ciliary muscle. Founded by ophthalmologist Dr. Liane Clamen, the company aims to replace the cataract-clouded natural lens with one that restores clear vision across near, intermediate, and distance ranges without glasses, contacts, or the halos and glare common to multifocal alternatives. Adaptilens raised a $17.5M Series A in April 2024 to advance its A-IOL toward first-in-human trials.
Liane Clamen
Liane Clamen is a Harvard-trained ophthalmologist and the founder and CEO of Adaptilens, a Newton, Massachusetts biotech building a biomimetic accommodating intraocular lens that imitates the young human lens so cataract patients can see near, intermediate, and distance without glasses. She sketched the idea more than two decades ago, fought the patent office to a 2019 grant, and in April 2024 closed a $17.5 million Series A to push the device toward its first human trial.